Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.87 |
| ▸ | SLC5A1 | P13866 | 12/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13110354 | 0.92 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL3045020 | 0.85 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL2580795 | 0.85 | SLC5A2 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL3045028 | 0.84 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL3045025 | 0.84 | SLC5A2 (0.63) | SLC5A2SLC5A1 | |
| SCHEMBL13110359 | 0.83 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL13110355 | 0.83 | SLC5A2 (0.81) | SLC5A2SLC5A1 | |
| SCHEMBL13110406 | 0.82 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL13110384 | 0.81 | SLC5A2 (1.00) | SLC5A2SLC5A1 | |
| SCHEMBL6013302 | 0.81 | SLC5A2 (1.00) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-7820630-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-26 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2010-01-14 | — | — | US | disclosed |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2009-04-23 | — | — | US | disclosed |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | BEAVERS MARY PAT | 2009-04-23 | — | — | US | disclosed |
| US-7511022-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
| US-7511022-B2 | Substituted indole-O-glucosides | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009900-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | SLC5A2 10/4885SLC5A1 14/4885 |
| US-20090105164-A1 | SUBSTITUTED INDOLE-O-GLUCOSIDES | GPR119, PYGL, IAPP | SLC5A2 10/4885SLC5A1 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.